MX2010014003A - Mediadores de peptido mejorados de eflujo de colesterol. - Google Patents

Mediadores de peptido mejorados de eflujo de colesterol.

Info

Publication number
MX2010014003A
MX2010014003A MX2010014003A MX2010014003A MX2010014003A MX 2010014003 A MX2010014003 A MX 2010014003A MX 2010014003 A MX2010014003 A MX 2010014003A MX 2010014003 A MX2010014003 A MX 2010014003A MX 2010014003 A MX2010014003 A MX 2010014003A
Authority
MX
Mexico
Prior art keywords
polypeptide
peptide
group
isolated
accordance
Prior art date
Application number
MX2010014003A
Other languages
English (en)
Spanish (es)
Inventor
Jan Johansson
John K Bielicki
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2010014003A publication Critical patent/MX2010014003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010014003A 2008-06-18 2009-06-17 Mediadores de peptido mejorados de eflujo de colesterol. MX2010014003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18
PCT/US2009/047694 WO2009155366A2 (en) 2008-06-18 2009-06-17 Improved peptide mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
MX2010014003A true MX2010014003A (es) 2011-02-15

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014003A MX2010014003A (es) 2008-06-18 2009-06-17 Mediadores de peptido mejorados de eflujo de colesterol.

Country Status (14)

Country Link
US (1) US8415293B2 (cg-RX-API-DMAC10.html)
EP (1) EP2300038A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011525181A (cg-RX-API-DMAC10.html)
KR (1) KR20110043597A (cg-RX-API-DMAC10.html)
CN (1) CN102123722A (cg-RX-API-DMAC10.html)
AU (1) AU2009260024A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0915422A2 (cg-RX-API-DMAC10.html)
CA (1) CA2727465A1 (cg-RX-API-DMAC10.html)
CL (1) CL2010001445A1 (cg-RX-API-DMAC10.html)
IL (1) IL209868A0 (cg-RX-API-DMAC10.html)
MX (1) MX2010014003A (cg-RX-API-DMAC10.html)
PE (1) PE20110106A1 (cg-RX-API-DMAC10.html)
RU (1) RU2011101536A (cg-RX-API-DMAC10.html)
WO (1) WO2009155366A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
US10532105B2 (en) * 2015-07-10 2020-01-14 Peptinovo Biopharma, LLC. Formulations for improving the efficacy of hydrophobic drugs
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609B (zh) * 2021-05-08 2026-07-28 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1706131A4 (en) 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
ATE533783T1 (de) 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux

Also Published As

Publication number Publication date
EP2300038A2 (en) 2011-03-30
CL2010001445A1 (es) 2012-03-16
WO2009155366A2 (en) 2009-12-23
RU2011101536A (ru) 2012-07-27
IL209868A0 (en) 2011-02-28
CA2727465A1 (en) 2009-12-23
CN102123722A (zh) 2011-07-13
WO2009155366A3 (en) 2010-04-22
JP2011525181A (ja) 2011-09-15
AU2009260024A1 (en) 2009-12-23
PE20110106A1 (es) 2011-03-02
EP2300038A4 (en) 2013-09-04
KR20110043597A (ko) 2011-04-27
US20110190196A1 (en) 2011-08-04
BRPI0915422A2 (pt) 2017-06-27
US8415293B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
US8415293B2 (en) Peptide mediators of cholesterol efflux
US11434267B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
US8987192B2 (en) Potent and selective mediators of cholesterol efflux
Li et al. Asteropsins B–D, sponge-derived knottins with potential utility as a novel scaffold for oral peptide drugs
US20250032580A1 (en) Use of adnf polypeptides in therapy
TW201021822A (en) Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US20220306710A1 (en) Treating alzheimer's disease
US20130123173A1 (en) Creation of oxidation-resistant hdl mimetic peptides
US20130225508A1 (en) Peptide capable of binding to immunoglobulin
US20250032581A1 (en) Compositions and articles comprising an adnf polypeptide
US20150031598A1 (en) Nemo binding domain fusion proteins
HK1138292B (en) Potent and selective mediators of cholesterol efflux
US11091529B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
TW201625678A (zh) 合成肽
JP2006016347A (ja) 学習記憶促進剤、学習記憶を促進する方法
EP2817324A1 (en) Nemo binding domain fusion proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal